Immune checkpoint inhibitors (ICI) have improved survival in metastatic melanoma, yet up to 60% of patients may not benefit. This study evaluated circulating Ki67⁺ CD4+ T-regulatory cells (Tregs) as a potential biomarker of response to ICIs. Increased Ki67 expression by CD4⁺ Tregs w...
The Verdict
ClassificationLikely AI
ConfidenceHigh confidence
Analyzedtext
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/aed5041d-6c10-4d31-be97-6a931a3d4257)